Pimecrolimus
| Evidence Level: L2 | Predicted Indications: 3 |
Table of Contents
Pimecrolimus: From Atopic Dermatitis to Seborrheic Dermatitis
One-Sentence Summary
Pimecrolimus is a topical calcineurin inhibitor, originally used to treat atopic eczema (atopic dermatitis). The TxGNN model predicts it may be effective for Seborrheic Dermatitis, with 1 completed Phase 2 randomized trial and about 19 publications (including 2 systematic reviews of randomized trials) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Atopic eczema / atopic dermatitis |
| Predicted New Indication | Seborrheic dermatitis |
| TxGNN Prediction Score | 0.9973 |
| Evidence Level | L2 |
| India Market Status | Listed in a compiled Indian medicine price dataset (6 of 6) – CDSCO approval status is not included in this data |
| Number of Listed Products | 6 (valid: 6) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known class pharmacology, pimecrolimus is a topical calcineurin inhibitor. It blocks T-cell activation and the release of inflammatory cytokines such as IL-2, IL-4, interferon-gamma and TNF-alpha, and it also inhibits mast cell degranulation.
Atopic dermatitis and seborrheic dermatitis are both chronic, relapsing inflammatory skin diseases with an immune-mediated component. Seborrheic dermatitis is also linked to inflammatory responses to Malassezia yeast on the skin. A non-steroidal anti-inflammatory agent is attractive here because long-term topical corticosteroid use on the face carries well-known adverse effects.
The very high TxGNN score is consistent with this reasoning. The published reviews support it: two systematic reviews of randomized trials describe pimecrolimus 1% cream as well tolerated and effective in seborrheic dermatitis, with efficacy comparable to the active comparators evaluated.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00403559 | Phase 2 | Completed | 113 | 4-week randomized, double-blind, active-comparator study of Elidel (pimecrolimus) in seborrheic dermatitis; exploratory study of effectiveness |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36072203 | 2022 | Systematic review of RCTs | Cureus | Reviews efficacy and safety of pimecrolimus in facial seborrheic dermatitis |
| 22142161 | 2012 | Systematic review of RCTs | Expert Rev Clin Pharmacol | Pimecrolimus 1% cream appears well tolerated and effective in seborrheic dermatitis, with efficacy comparable to comparators |
| 27804089 | 2017 | Systematic review | Am J Clin Dermatol | Topical treatments for facial seborrheic dermatitis (antifungals, keratolytics, corticosteroids) |
| 31053034 | 2019 | Review | J Cutan Med Surg | Off-label uses of topical pimecrolimus, focusing on published RCTs |
| 19222250 | 2009 | Review | Am J Clin Dermatol | Topical calcineurin inhibitors are a safe alternative to corticosteroids in seborrheic dermatitis |
| 20000875 | 2010 | Open-label study | Am J Clin Dermatol | Pimecrolimus 1% cream effective and well tolerated in resistant facial seborrheic dermatitis |
| 17982237 | 2007 | Open-label study (n=20) | J Korean Med Sci | 4 weeks of pimecrolimus 1% cream in Korean patients with facial seborrheic dermatitis |
| 16033622 | 2005 | Review | Int J Clin Pract | Pimecrolimus targets T cells and mast cells; use in atopic dermatitis and beyond |
| 17020422 | 2006 | Review | Expert Opin Pharmacother | Pimecrolimus for skin diseases other than atopic dermatitis |
| 19213227 | 2009 | Review | J Drugs Dermatol | Current status and therapeutic horizons for facial seborrheic dermatitis |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 178358 | Picon Lotion (Biocon) | 20 ml bottle, lotion | Not stated |
| 174334 | Picon Cream (Biocon) | 10 g tube, cream | Not stated |
| 174220 | Pacroma Cream (Ajanta Pharma) | 30 g tube, cream | Not stated |
| 72524 | Elidel Cream (Mylan) | 10 g tube, cream | Not stated |
| 173831 | Picon Cream (Biocon) | 30 g tube, cream | Not stated |
Safety Considerations
- Contraindications flagged in the knowledge graph (not label text): Viral and infectious skin conditions are flagged, including common wart, epidermodysplasia verruciformis, anogenital human papillomavirus infection, herpes simplex (including herpes simplex dermatitis), herpes zoster, chickenpox, infectious mononucleosis and chronic Epstein-Barr virus infection. Lymphatic system disease, Netherton syndrome and ichthyosis linearis circumflexa are also flagged.
- Drug Interactions: 103 interactions were found in the database, none with a severity rating. Examples include triamcinolone, prednisone, hydrocortisone, budesonide, omeprazole, pantoprazole, simvastatin, metformin, doxycycline and metronidazole.
- Related literature signals: Reviews note that topical calcineurin inhibitors can alter the appearance of fungal skin infections (tinea incognito). A 2023 systematic review and meta-analysis examined cancer risk with topical calcineurin inhibitors, and a 10-year pediatric registry of Elidel use is ongoing.
For full warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed Phase 2 randomized, double-blind, active-comparator trial and two systematic reviews of randomized trials support pimecrolimus in seborrheic dermatitis, and the product is already marketed in India as a topical cream. The evidence is promising but not definitive: the trial was exploratory, and no Phase 3 confirmation is available.
To proceed, the following is needed:
- Package insert warnings and contraindications, which are currently missing and block formal safety screening
- Detailed mechanism of action data from DrugBank
- Full results of NCT00403559 and, ideally, a confirmatory Phase 3 trial in seborrheic dermatitis
- Confirmation of the approved indications for the Indian products, since none are listed in the licence data
- Guardrails: restrict use to second-line, short-term, intermittent treatment, respect age limits, and avoid use on infected skin (viral or fungal)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.